Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRK Stock Forecast 2025-2026
$77.84
Current Price
$193.81B
Market Cap
Buy 15
Hold 11
Sell 0
Wall St Analyst Ratings
Distance to MRK Price Targets
+77.3%
To High Target of $138.00
+28.5%
To Median Target of $100.00
+5.3%
To Low Target of $82.00
MRK Price Momentum
+2.3%
1 Week Change
-1.1%
1 Month Change
-40.6%
1 Year Change
-21.8%
Year-to-Date Change
-42.2%
From 52W High of $134.63
+6.2%
From 52W Low of $73.31
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Merck (MRK) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MRK and similar high-potential opportunities.
Latest MRK Stock Price Targets & Analyst Predictions
Based on our analysis of 38 Wall Street analysts, MRK has a bullish consensus with a median price target of $100.00 (ranging from $82.00 to $138.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $77.84, the median forecast implies a 28.5% upside. This outlook is supported by 15 Buy, 11 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Harrison at Morgan Stanley, suggesting a 5.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRK Analyst Ratings
15
Buy
11
Hold
0
Sell
MRK Price Target Range
Low
$82.00
Average
$100.00
High
$138.00
Current: $77.84
Latest MRK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Citigroup | Andrew Baum | Neutral | Downgrade | $84.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Neutral | Initiates | $85.00 |
| Apr 17, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $115.00 |
| Feb 18, 2025 | Deutsche Bank | James Shin | Hold | Downgrade | $105.00 |
| Feb 12, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $115.00 |
| Feb 5, 2025 | Citigroup | Andrew Baum | Buy | Maintains | $115.00 |
| Feb 5, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $106.00 |
| Feb 5, 2025 | BMO Capital | Evan David Seigerman | Market Perform | Maintains | $96.00 |
| Feb 5, 2025 | B of A Securities | Tim Anderson | Buy | Maintains | $112.00 |
| Jan 28, 2025 | Citigroup | Andrew Baum | Buy | Maintains | $125.00 |
| Jan 21, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $113.00 |
| Jan 13, 2025 | Leerink Partners | Daina Graybosch | Outperform | Maintains | $119.00 |
| Jan 8, 2025 | UBS | Colin Bristow | Buy | Maintains | $120.00 |
| Jan 8, 2025 | Truist Securities | Robyn Karnauskas | Hold | Downgrade | $110.00 |
| Dec 20, 2024 | BMO Capital | Evan David Seigerman | Market Perform | Downgrade | $105.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Buy | Reinstates | $121.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Peer Perform | Initiates | $0.00 |
| Nov 7, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $130.00 |
| Nov 6, 2024 | Guggenheim | Seamus Fernandez | Buy | Maintains | $130.00 |
| Nov 1, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $123.00 |
Merck & Co., Inc. (MRK) Competitors
The following stocks are similar to Merck based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Merck & Co., Inc. (MRK) Financial Data
Merck & Co., Inc. has a market capitalization of $193.81B with a P/E ratio of 11.2x. The company generates $63.92B in trailing twelve-month revenue with a 27.3% profit margin.
Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of +40.1% and return on equity of +39.3%.
Valuation Metrics
Market Cap
$193.81B
Enterprise Value
$218.98B
P/E Ratio
11.2x
PEG Ratio
8.2x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
-1.6%
Gross Margin
+78.0%
Operating Margin
+40.1%
Net Margin
+27.3%
EPS Growth
+6.7%
Financial Health
Cash/Price Ratio
+4.7%
Current Ratio
1.4x
Debt/Equity
72.0x
ROE
+39.3%
ROA
+13.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Merck & Co., Inc. (MRK) Business Model
About Merck & Co., Inc.
What They Do
Develops pharmaceuticals and vaccines for health.
Business Model
The company generates revenue through the research, development, production, and marketing of innovative drugs and vaccines. It focuses on key therapeutic areas such as oncology, infectious diseases, and diabetes, while also addressing animal health through veterinary products. This diverse portfolio allows Merck to cater to various healthcare needs across global markets.
Additional Information
Merck is heavily invested in research and development, with a strong pipeline of new products aimed at advancing medical breakthroughs. Its commitment to public health initiatives and veterinary services highlights its comprehensive approach to improving health outcomes for both humans and animals.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73,000
CEO
Mr. Robert M. Davis J.D.
Country
United States
IPO Year
1970
Website
www.merck.comMerck & Co., Inc. (MRK) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
May 21, 2025
By Kinjel Shah
Analyst Blog
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
May 20, 2025
By Zacks Equity Research
Analyst Blog
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
May 20, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
The IDeate-Esophageal01 study will assess Merck and Daiichi's ADC drug ifinatamab deruxtecan in patients with pre-treated esophageal squamous cell carcinoma.
Why It Matters
The IDeate-Esophageal01 study's evaluation of ifinatamab deruxtecan could impact Merck & Daiichi's market position and future revenue, influencing stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Merck announced positive Phase 2 study results for enpatoran, an oral TLR7/8 inhibitor, showing significant disease activity reduction in patients with cutaneous and systemic lupus erythematosus.
Why It Matters
Positive Phase 2 data on enpatoran for lupus could enhance Merck's product pipeline, potentially leading to market approval and increased revenue, impacting stock performance favorably.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Merck will participate in the Bernstein 41st Annual Strategic Decisions Conference, indicating engagement with investors and potential strategic discussions.
Why It Matters
Merck's participation in a key conference signals potential updates on strategy and growth opportunities, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors often seek dividend-yielding stocks in turbulent markets, as these companies typically have strong cash flows and provide high dividend payouts.
Why It Matters
Dividend-yielding stocks attract investors during market volatility, indicating strong cash flow and stability, which can provide income and reduce portfolio risk amidst uncertainty.
Source: Benzinga
Market Sentiment:
Positive
Merck: Undervalued In Light Of Key Risks
1 day ago
Quick Summary
Merck & Co. is currently undervalued with lower trading multiples than peers. Keytruda boosts oncology performance amid revenue growth, while R&D and manufacturing investments support future expansion.
Why It Matters
Merck's undervaluation amid patent concerns offers a buying opportunity. Strong oncology performance and R&D investments position it well for future growth despite current challenges.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Financial media is searching for a market bottom, which may have been reached. The Federal Reserve is unlikely to lower rates this summer despite presidential pressure.
Why It Matters
Speculation about a market bottom can influence investor sentiment, while stable interest rates from the Fed may impact borrowing costs and investment decisions.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Frequently Asked Questions About MRK Stock
What is Merck & Co., Inc.'s (MRK) stock forecast for 2025?
Based on our analysis of 38 Wall Street analysts, Merck & Co., Inc. (MRK) has a median price target of $100.00. The highest price target is $138.00 and the lowest is $82.00.
Is MRK stock a good investment in 2025?
According to current analyst ratings, MRK has 15 Buy ratings, 11 Hold ratings, and 0 Sell ratings. The stock is currently trading at $77.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRK stock?
Wall Street analysts predict MRK stock could reach $100.00 in the next 12 months. This represents a 28.5% increase from the current price of $77.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Merck & Co., Inc.'s business model?
The company generates revenue through the research, development, production, and marketing of innovative drugs and vaccines. It focuses on key therapeutic areas such as oncology, infectious diseases, and diabetes, while also addressing animal health through veterinary products. This diverse portfolio allows Merck to cater to various healthcare needs across global markets.
What is the highest forecasted price for MRK Merck & Co., Inc.?
The highest price target for MRK is $138.00 from at , which represents a 77.3% increase from the current price of $77.84.
What is the lowest forecasted price for MRK Merck & Co., Inc.?
The lowest price target for MRK is $82.00 from Matthew Harrison at Morgan Stanley, which represents a 5.3% increase from the current price of $77.84.
What is the overall MRK consensus from analysts for Merck & Co., Inc.?
The overall analyst consensus for MRK is bullish. Out of 38 Wall Street analysts, 15 rate it as Buy, 11 as Hold, and 0 as Sell, with a median price target of $100.00.
How accurate are MRK stock price projections?
Stock price projections, including those for Merck & Co., Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 4:51 AM UTC